Sadol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sadol

Defining Sadol: What Kind of Drug Is It?

Property Description
Active Ingredient Fenbufen
INN & Class Fenbufen; Non-Steroidal Anti-Inflammatory Drug (NSAID)
Form Oral tablets or capsules
General Purpose Symptomatic relief of pain and inflammation
Distinguishing Feature Classified as a pro-drug

Sadol is an established Non-Steroidal Anti-Inflammatory Drug (NSAID), known by the International Nonproprietary Name (INN) of Fenbufen. It belongs to the propionic acid derivative subclass of NSAIDs and is administered orally, commonly found as film-coated tablets or capsules. As an NSAID, its fundamental role is to modulate the body's inflammatory and pain responses to provide symptomatic relief.


The Makeup of Sadol: Composition and Differentiation

Fenbufen is a synthetic compound, meaning the active ingredient is entirely manufactured through chemical processes. Its most distinguishing feature is its classification as a pro-drug. This means the compound itself is largely inactive upon ingestion and must be metabolized by the body into its active form, biphenylacetic acid (BPAA). Under this mechanism, the active metabolite serves as the potent inhibitor of prostaglandin synthesis.


General Purpose: What Sadol Addresses

The general therapeutic purpose of Sadol (Fenbufen) is the effective management of conditions involving pain and inflammation. It is broadly indicated for reducing discomfort associated with chronic inflammatory conditions, such as rheumatoid arthritis and osteoarthritis, as well as various soft-tissue injuries. For example, it is frequently used to manage localized pain and swelling. Its action helps patients achieve functional relief, though it does not cure the underlying cause of the inflammatory disease.

What side effects are possible with Sadol?

Possible Side Effects of Sadol

Sadol (butorphanol) is an opioid pain reliever and, like all opioids, carries risks and potential side effects that patients should be aware of. Side effects often vary in frequency and severity.

Common Side Effects

The most frequently reported side effects of Sadol, occurring in 1% or more of patients, often involve the central nervous system and gastrointestinal tract. These may include:

  • Drowsiness or sedation
  • Dizziness
  • Nausea and vomiting
  • Dry mouth
  • Insomnia

Serious and Infrequent Adverse Reactions

Sadol use is associated with a risk of serious side effects. Patients should seek immediate medical attention if they experience any signs of the following:

  • Respiratory Depression: Slowed, shallow, or difficult breathing, which can be life-threatening. This risk is highest upon starting treatment or increasing the dosage.
  • Severe Central Nervous System (CNS) Effects: Hallucinations, confusion, or agitation.
  • Cardiovascular Changes: High blood pressure (hypertension), fast or pounding heartbeats (tachycardia).
  • Gastrointestinal Issues: Severe constipation, which may lead to more serious complications.
  • Allergic Reactions: Hives, rash, swelling of the face, lips, tongue, or throat, or trouble breathing.

Safety Information and Warnings

Risk of Dependence and Abuse: Sadol has the potential for addiction, abuse, and misuse, which can lead to overdose and death. It should be used only as prescribed.

Interactions: The concomitant use of Sadol with other Central Nervous System (CNS) depressants, including alcohol and benzodiazepines, significantly increases the risk of profound sedation, respiratory depression, coma, and death. Patients must discuss all medications, supplements, and alcohol use with their healthcare provider.

Discontinuation: Sudden discontinuation of Sadol after prolonged use can lead to opioid withdrawal symptoms. A gradual dose reduction may be required under medical supervision.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Sadol (Fenbufen) is officially documented to present with a spectrum of clinical manifestations affecting the gastrointestinal (GI) and central nervous system (CNS). Common initial signs described in regulatory documents include nausea, vomiting, epigastric pain, headache, and drowsiness.

Severe, life-threatening outcomes following substantial ingestions are classified as potentially involving major systemic toxicity, including cardiovascular shock, seizures, coma, metabolic acidosis, and acute renal failure. Symptoms can be delayed; therefore, medical observation is required.

Regulatory documents mandate that immediate action must be taken. Individuals are required to contact a Poison Control Center or emergency services immediately following any suspected overdose or the onset of any of the above-listed symptoms. The management of Fenbufen overdose is entirely supportive, as no specific antidote is officially known or described in regulatory labeling.

Supportive care procedures are the focus, including measures to ensure adequate hydration to help mitigate the risk of severe complications like acute renal failure. Monitoring is required for all symptomatic individuals and all cases of intentional overdose.

Therapeutic Uses of Sadol

What Sadol Treats: Main Uses and Benefits

Sadol (Fenbufen) is commonly used for symptoms related to physical discomfort and inflammation. It may assist with managing periods of heightened symptoms and functional strain. Its primary therapeutic role is applied in addressing inflammatory and painful musculoskeletal disorders.

This medication is commonly used to support patients facing conditions characterized by periods of heightened symptoms, such as rheumatoid arthritis and osteoarthritis. It is applied in addressing the burden of symptoms that may intensify temporarily. This supportive relief plays a role in managing long-term joint distress, pain, and stiffness. Sadol may assist with easing discomfort in conditions presenting with systemic or localized discomfort, which may include ankylosing spondylitis, tendinitis, soft-tissue injuries, and acute gouty arthritis.

“It may help address symptoms that create noticeable physiological strain, and supports the patient during phases when symptoms become more noticeable.”

Sadol assists with maintaining functional stability when chronic manifestations interfere with routine activities. The medication is considered relevant in clinical settings requiring short-term symptomatic assistance for acute or disruptive episodes, helping to reduce localized swelling and tenderness during a flare-up phase.

Quick Fact: Relief for Pain and Inflammation
This medication may assist with managing symptoms that create noticeable physiological strain, used in situations involving certain distressing symptoms such as joint pain.

Eligibility and Restrictions for Use

Official Eligibility Status

Regulatory agencies define the eligible patient population for Sadol (Fenbufen), which is a Non-Steroidal Anti-Inflammatory Drug (NSAID), based on age, pre-existing conditions, and physiological state.

Contraindicated Populations Restricted/Conditional Use
Hypersensitivity to fenbufen, aspirin, or any other NSAID. Older Adults (Increased risk of adverse effects; require special consideration).
Active Gastrointestinal Disease (e.g., peptic ulceration or hemorrhage). Impaired Organ Function (Renal or hepatic impairment may require dosage adjustment or avoidance in severe cases).
Pregnancy from 20 Weeks Gestation onward. Pediatric Patients (Use is often not established or not recommended below a specific age).

Pregnancy and Lactation Eligibility:

Use of Sadol is contraindicated starting at 20 weeks of pregnancy due to documented risks to the fetus. The drug is not recommended for patients who are breastfeeding, as its status and safety in this population are generally not established in official labeling. The medicine is primarily intended for use in adults who do not possess these documented limiting factors or prohibiting conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sadol (butorphanol) is known to interact with several classes of medicinal products, which can lead to clinically significant or life-threatening adverse reactions.

Interacting Product Category Potential Risk Management Restriction
CNS Depressants (e.g., Benzodiazepines, sedatives, tranquilizers, other opioids, alcohol) Profound sedation, respiratory depression, coma, and death due to additive pharmacologic effect. Reserve concomitant use for when alternatives are inadequate; limit dosage and duration to the minimum required.
Serotonergic Drugs (e.g., SSRIs, SNRIs, Triptans) Serotonin syndrome, a potentially life-threatening condition. Monitor the patient closely, especially during treatment initiation and dose adjustments. Discontinue Sadol if serotonin syndrome is suspected.
Monoamine Oxidase Inhibitors (MAOIs) Risk is not fully established due to lack of information. Concomitant use should be avoided.
CYP3A4 Inhibitors or Inducers Increased or decreased Sadol plasma concentrations, which could prolong or reduce effects. Monitor the patient for altered response; a reduced starting dose or longer intervals may be considered if using an inhibitor.

Patients should be aware of the serious, potentially fatal risks associated with the co-administration of Central Nervous System depressants, including alcohol, due to their additive effects on the nervous system. The potential for Serotonin Syndrome also requires frequent patient evaluation when Sadol is combined with other serotonergic agents. It is essential to communicate all concurrent medications and supplements to a healthcare provider to manage these interaction risks.

Mechanism of Action

The action of Sadol is achieved by modulating the activity of the body’s primary eicosanoid cascade, which regulates inflammatory signaling. Its mechanism is defined by a mandatory metabolic conversion followed by targeted enzyme inhibition.

Sadol (Fenbufen) is classified as a pro-drug, meaning the administered compound is pharmacologically inert until the body metabolizes it into its active form, 4-Biphenylacetic acid (BPAA). This initial conversion step governs the drug's overall mechanism, as the time required to initiate enzyme inhibition is intrinsically linked to the rate of active metabolite generation.

The active metabolite, BPAA, exerts its effect by acting as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically targeting both COX-1 and COX-2 isoforms. By blocking these key enzymes, the drug interferes with the metabolic pathway that converts arachidonic acid into pro-inflammatory mediators.

The suppression of COX activity leads to a reduction in the synthesis of prostaglandins (PGs), which are chemical messengers in the inflammatory process. This mechanistic cascade results in the physiological consequence of reduced peripheral nerve sensitization and attenuated local vascular changes, which alters signaling dynamics within the targeted pathways.

Dosage and Administration Information

Sadol (Fenbufen) is administered exclusively via the oral route, available in official dosage forms as tablets or capsules. Standard usage protocols define specific dosage limits and required frequency patterns.

The standard adult dosing range for this medication is generally set between 600 mg and 1000 mg per day (1.0 g). The established maximum total daily intake must not exceed 1000 mg. The frequency of administration is typically structured as divided use, most commonly taken in two doses per day (twice daily) to ensure consistent delivery of the active metabolite.

Regarding timing and conditions of use, the oral dose may be taken with or without food. While the presence of food can delay the rate at which the medication is absorbed, the total amount of Fenbufen absorbed remains generally consistent. Due to a lack of established guidelines, the administration of Sadol is restricted to adults, and its use in pediatric populations is not recommended. For chronic administration, the full anti-inflammatory action may require continuous usage for a period of two to three weeks before its final efficacy can be properly assessed. This protocol describes the parameters for the drug's application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sadol (Fenbufen)


Evidence for Use in Osteoarthritis

Research was studied for conditions characterized by fluctuating or episodic manifestations such as osteoarthritis. The evidence base includes Randomized Controlled Trials (RCTs) and studies where patients were observed in comparison to an inactive placeholder. These trials examined patient-reported experiences and outcomes related to physical discomfort and daily functioning.

The studies monitored outcomes such as pain levels, joint swelling, and tenderness over defined time intervals. Findings contribute to understanding symptom patterns over the short-term follow-up periods (e.g., 4 to 6 weeks). When compared to an inactive placeholder, research describes data show patterns related to measurements in pain and functional scores. However, the evidence base is limited regarding outcomes reflecting daily functioning or activity level beyond these short durations.


Evidence for Use in Rheumatoid Arthritis

Sadol was studied for research settings involving conditions associated with acute or disruptive episodes like rheumatoid arthritis. These studies included Double-Blind Cross-Over Trials and Parallel Group Comparison Studies, often observing the drug alongside older anti-inflammatory medicines. The research examined outcomes linked to inflammatory or irritative states and systemic or functional imbalance.

Researchers monitored changes in disease activity, specifically tracking key symptoms such as the duration of morning stiffness and the number of swollen and tender joints. The reported outcomes often described patterns of outcomes related to systemic or functional imbalance measured in the studied populations. A key limitation is that evidence is largely derived from older comparative trials, and comparative evidence is lacking against many contemporary targeted therapies.


Research Gaps and Uncertainty

Research for acute pain is mainly limited to Single-Dose Randomized Controlled Trials (RCTs). The overall certainty in this area remains low, as systematic reviews have noted that the data for certain groups remain insufficient. Furthermore, sample sizes were modest in some pivotal trials, meaning the findings describe group patterns, not personal outcomes, and may not be broadly generalizable. Evidence quality varies across studies, and long-term effects beyond several months are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Sadol (FAQ)

Q: Is it normal to feel [non-serious symptom like mild headache] when first starting Sadol?

According to official product information, common side effects such as headache, dizziness, or nausea have been reported in clinical trials. These effects are described as more likely to be reported during the initial phase of exposure to the medication. Regulatory statements describe common population patterns, not individual outcomes.

Q: Does Sadol interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

Official guidance indicates that concomitant use with other pain relievers, including other non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen, is generally not recommended due to an increased risk of side effects. Questions regarding co-administration should be addressed by a healthcare provider.

Q: Why do some people say Sadol did not work for them?

Studies and official information indicate that the full anti-inflammatory effect may require continuous use for two to three weeks before efficacy can be properly assessed. Individual responses to medication are also observed to vary. Research findings are based on observed group patterns and do not predict or describe individual patient outcomes.

Q: What is the maximum amount of time a person can safely be on Sadol?

Regulatory documents indicate that therapy is generally guided by using the lowest effective dosage for the shortest duration necessary. The full extent of safety data for long-term effects beyond several months is not fully established. Duration of use is determined by a healthcare provider based on the condition being addressed.

Q: Can I drive or operate heavy machinery while taking Sadol?

Official regulatory warnings state that this medication may impair the mental and physical abilities required for potentially hazardous tasks such as driving or operating machinery. A cautious approach involves temporarily avoiding these activities until the individual effect of the medication is known.

Q: Will Sadol make me feel 'out of it' or affect my ability to focus?

The official product information lists central nervous system (CNS) effects as possible side effects. These can include dizziness, sedation, or confusion, all of which may affect concentration and alertness. The severity and likelihood of these effects are observed to vary among the studied population.

Q: How quickly should I expect to feel the effects of Sadol?

Pharmacological data for the NSAID component (Fenbufen) reports the onset of action occurs within one hour. However, the full magnitude of therapeutic benefit may require a longer duration of use, especially for chronic inflammatory conditions.

Q: How long does Sadol stay in your system?

Pharmacokinetic data from official sources indicate that the plasma half-life of the active metabolite of the NSAID component is approximately 10 to 17 hours. The reported half-life is a measure used to describe how long the active substance remains present in the plasma.

Q: Is Sadol considered a long-term or short-term treatment?

The product is generally intended for short-term use, especially when prescribed for pain relief. In chronic inflammatory conditions, long-term use may be considered when alternatives are determined to be inadequate. Duration of use is determined by the specific condition being treated, based on regulatory guidelines.

Q: Does Sadol cause weight gain or weight loss?

Official product information notes that side effects can include fluid retention (edema), which may contribute to weight gain. Conversely, weight loss has also been reported as a less common adverse reaction. Any observed changes in weight may warrant discussion with a healthcare provider.

Q: Can Sadol be taken at the same time as my daily vitamin or supplement?

Regulatory advice emphasizes the need for patients to inform their healthcare provider of all concomitant products. This includes prescription and over-the-counter medicines, as well as vitamins, minerals, herbal products, and other supplements. Disclosure of all concomitant products is a general practice intended to identify potential interaction risks.

Q: Is Sadol known to interact with caffeine?

Official warnings state that concomitant use with other Central Nervous System (CNS) depressants may cause additive effects. These effects can lead to profound sedation or respiratory depression. Situations involving the simultaneous use of CNS depressants or stimulants are typically assessed by a healthcare provider.

Q: Can Sadol affect the results of certain medical tests or lab work?

Clinical study data related to the NSAID component has reported temporary elevations of alkaline phosphatase and serum transaminase levels. These values often return to normal with continued use. Clinical guidelines indicate that laboratory monitoring may be considered when assessing patient risks.

Q: Are there any known interactions between Sadol and herbal remedies like St. John's Wort?

Regulatory warnings caution against the use of any serotonergic drug, which includes certain herbal remedies. Combining these with Sadol may increase the risk of Serotonin Syndrome, a potentially life-threatening condition. Disclosure of all herbal products being consumed is recommended.

Q: Does taking Sadol require any specific monitoring or regular blood tests?

The necessity of blood and urine tests for monitoring unwanted effects, as well as clinical and laboratory surveillance, is determined based on existing patient risk factors. This monitoring is typically done to assess organ function, such as kidney or liver health.

Q: What is the purpose of the black box warning on Sadol (if applicable/known in general)?

As an opioid analgesic, the drug is subject to a Boxed Warning—the strongest warning issued by the FDA—to highlight the most serious risks. These include addiction, abuse, misuse, life-threatening respiratory depression, and Neonatal Opioid Withdrawal Syndrome. These warnings communicate risks based on established regulatory safety evaluations.

Q: Does Sadol interact with birth control pills?

The use of some opioid-containing medications is described as having the potential to decrease the effectiveness of hormonal contraceptives. Due to this potential interaction, alternative or additional birth control methods may be required for risk mitigation.

Q: Does Sadol affect fertility or the ability to have children?

Official warnings state that the long-term use of the opioid component of Sadol may cause reduced fertility. While this risk is noted, it is not known whether these effects on the ability to have children are reversible. Concerns regarding fertility or reproductive effects are typically addressed by a healthcare provider.

How should Sadol be stored and disposed of?

The storage and disposal of Sadol (Fenbufen) must strictly follow the conditions defined in the official regulatory documents.

Sadol tablets must be stored at ambient temperature, typically between 15 C and 25 C (59 F and 77 F), though stability may be tested up to 30 C. The medication requires protection from light and must be kept in a dry place inside a sealed container.


Required Storage and Disposal

Classification Requirement
Container Integrity Store in a sealed container; keep tightly closed.
Child Safety Keep out of the sight and reach of children (store locked up).
Disposal Rule Dispose of contents according to official local regulations; prevent entry into drains.

This medicine must not be placed into the sewage system. Unused or expired product should be discarded using an authorized drug take-back program or following the FDA-recommended method for non-flushable medicines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sadol found in:

A-Z Index: